title: Trimetazidine Prevention of Contrast-Induced Nephropathy in Coronary Angiography.
abstract: BACKGROUND
  Contrast-induced nephropathy (CIN) after coronary angiography is frequently observed in patients with chronic renal insufficiency and no effective measures have been developed for prevention of CIN. There is evidence showing that trimetazidine (TMZ) has renoprotective effect on CIN. This study was to evaluate the role of TMZ in the prevention of CIN in renal dysfunction patients undergoing coronary angiography.
  
  
  METHODS
  A total of 132 patients with renal dysfunction who underwent coronary angiography were enrolled in our study and divided into control group (n = 70) and TMZ group (n = 62). Standard hydration was administered in all the patients. In TMZ group, patients were administered TMZ orally for 48 hours before and 24 hours after coronary angiography. Serum creatinine (SCr) and cystatin (CysC) were detected before and after contrast media injection, and the incidence of CIN was evaluated according to the elevation of SCr. Adverse events were observed in 12 months.
  
  
  RESULTS
  In both groups, CysC and SCr increased significantly after coronary angiography and peaked at 24 and 48 hours, respectively. CysC and SCr were significantly lower in TMZ group than in control group after coronary angiography. The incidence of CIN and adverse events was reduced in TMZ group when compared with control group (P = 0.034 and P = 0.043, respectively).
  
  
  CONCLUSIONS
  TMZ in combination with standard hydration is more effective than isotonic saline alone in protecting renal function in patients with renal dysfunction who undergo coronary angiography and can reduce the adverse events within 12 months.
authors.affiliation: Department of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
authors.forename: Weijing
authors.initials: W
authors.lastname: Liu
authors.forename: Qiang
authors.initials: Q
authors.lastname: Ming
authors.forename: Jianying
authors.initials: J
authors.lastname: Shen
authors.forename: Yidong
authors.initials: Y
authors.lastname: Wei
authors.forename: Weiming
authors.initials: W
authors.lastname: Li
authors.forename: Wei
authors.initials: W
authors.lastname: Chen
authors.forename: Yawei
authors.initials: Y
authors.lastname: Xu
mesh_terms: D000368:Aged; D003287:Contrast Media / Q000009:adverse effects*; D017023:Coronary Angiography / Q000009:adverse effects / Q000379:methods; D003324:Coronary Artery Disease / Q000150:complications / Q000175:diagnosis; D003404:Creatinine / Q000097:blood; D055316:Cystatin C / Q000097:blood; D016903:Drug Monitoring; D005260:Female; D005440:Fluid Therapy / Q000379:methods; D006801:Humans; D007677:Kidney Function Tests / Q000379:methods; D008297:Male; D008875:Middle Aged; D020011:Protective Agents / Q000008:administration & dosage; D051436:Renal Insufficiency, Chronic / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000628:therapy; D055502:Secondary Prevention / Q000379:methods; D016896:Treatment Outcome; D014292:Trimetazidine / Q000008:administration & dosage*
chemical_list: D003287:Contrast Media; D055316:Cystatin C; D020011:Protective Agents; D003404:Creatinine; D014292:Trimetazidine